Kathleen A. Neville

High Impact

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: Rutgers, The State University of New Jersey (1996); Arkansas Children's Hospital (2015–2022); Children's Mercy Hospital (2008–2015); Children's Hospital of Philadelphia (2004); Baylor College of Medicine (2002–2007); University of Arkansas Medical Center (2020–2022); NYU Langone Health (1994); Bellevue Hospital Center (1994); Indiana University Bloomington (2007); UPMC Hillman Cancer Center (2004); National Cancer Institute (2004); Pediatrics and Genetics (2015); Texas Children's Hospital (2002); Rainbow Babies & Children's Hospital (2004); Indiana University Indianapolis (2006); Indiana University School of Medicine (2005–2006); New York University (1994); University of Missouri–Kansas City (2008–2015)

29 h-index 86 pubs 4,355 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Kathleen A. Neville's research focuses on the pharmacological treatment of pediatric conditions, with a particular emphasis on off-label drug use and the safe transfer of therapeutics in vulnerable populations. Her work investigates the pharmacokinetics and pharmacodynamics of various drugs in children, addressing critical issues such as neonatal drug withdrawal and pain management. Neville has examined interethnic differences in drug metabolism, specifically the genetic polymorphisms of CYP2D6, and their clinical implications.

Her publications include studies on the transfer of drugs into human breast milk, the off-label use of medications in children, and the efficacy of specific treatments like bortezomib in pediatric cancer patients and brentuximab vedotin for relapsed or refractory lymphoma. Neville also explores pain assessment tools for children, such as the Numerical Rating Scale (NRS-11).

Neville's scholarship metrics indicate a significant body of work, with an h-index of 29 and 89 total publications, accumulating over 4,366 citations. She is recognized as a highly cited researcher. Her collaborations include work with Shelley E. Crary, Joana M. Mack, Gresham T. Richter, and Jeffery H. Moran, all from the University of Arkansas for Medical Sciences.

Metrics

h-index: 29
Publications: 86
Citations: 4,355

Selected Publications

Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion (2023)

1 citation DOI OpenAlex
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial (2022)

UCL Discovery (University College London) 74 citations OpenAlex
Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations (2022)

Pediatric Blood & Cancer 14 citations DOI OpenAlex
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion (2021)

eScholarship (California Digital Library) 16 citations OpenAlex
Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial (2020)

Pediatric Hematology and Oncology 19 citations DOI OpenAlex
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers (2020)

Oncotarget 41 citations DOI OpenAlex
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial (2020)

American Journal of Hematology 51 citations DOI OpenAlex
Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease (2020)

Pediatric Blood & Cancer 16 citations DOI OpenAlex
THER-21. TARGETING LIN28 WITH DFMO IN PATIENTS WITH ETMR SUGGESTS CLINICAL BENEFIT (2019)

Neuro-Oncology 1 citation DOI OpenAlex
Implementing a standard-of-care clinic for stroke prevention in children with sickle cell disease in Nigeria: a feasible strategy outside a clinical trial setting (2017)

Blood Advances 1 citation DOI OpenAlex
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (2017)

American Journal of Hematology 77 citations DOI OpenAlex
Pharmacokinetics of two 6‐mercaptopurine liquid formulations in children with acute lymphoblastic leukemia (2017)

Pediatric Blood & Cancer 8 citations DOI OpenAlex
The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy (2017)

Journal of Pediatric Oncology Nursing 4 citations DOI OpenAlex
Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial) (2016)

Blood 4 citations DOI OpenAlex
Pharmacokinetics in Children with Sickle Cell Anemia Following Single Dose Versus Chronic Treatment with Hydroxyurea (2016)

Blood 1 citation DOI OpenAlex